VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015 Jul; 107(7).
View in:
PubMed
subject areas
Animals
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Blotting, Western
Cell Line, Tumor
Cisplatin
Cystadenocarcinoma, Serous
DNA Damage
DNA, Neoplasm
Drug Synergism
Epithelial-Mesenchymal Transition
Female
Gene Expression Regulation, Neoplastic
HeLa Cells
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Mice
Mice, Nude
MicroRNAs
Microscopy, Fluorescence
Neoplasm Grading
Neoplasm Transplantation
Neoplasms, Experimental
Odds Ratio
Ovarian Neoplasms
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
Rad51 Recombinase
Real-Time Polymerase Chain Reaction
Tissue Array Analysis
Tumor Stem Cell Assay
authors with profiles
ANIL K SOOD
LINGEGOWDA SELANERE MANGALA